Presenters from SLEEP 2022 contextualized some of the recent research showing the impact of sleep disorders on aspects of mental health, including depressive symptoms and suicide.
During a presentation entitled “Sleep and Mental Health,” researchers gathered to contextualize some of the recent research showing the impact of sleep disorders on aspects of mental health, including depressive symptoms and suicide.
Insomnia and Depression Prediction
Past longitudinal studies have shown a link between insomnia and depression, but the underlying mechanisms of this relationship have not been fully realized. The researchers proposed that emotion regulation could be a potential mediating mechanism; however, empirical tests of the effect have been limited.
The researchers decided to conduct a study that would examine the individual relationship between insomnia and depressive symptoms over a 14-day period to assess whether insomnia symptoms on a given night would positively predict depressive symptoms the following day via emotion regulation.
In total, 60 adults between 18 and 65 years old with elevated insomnia symptoms, demonstrated by having an Insomnia Severity Index score of 10 or above, were enrolled in the analysis. The participants were tasked with filling out diary entries in the mornings and evenings and were given an actigraph to wear for 14 days.
The morning diary entries were to measure emotional reactivity using the International Positive and Negative Affect Schedule, emotional regulation strategy use through the Emotion Regulation Questionnaire and Cognitive Emotion Regulation Questionnaire, and depression, as determined by the Center for Epidemiologic Studies Depression Scale. The researchers utilized multilevel modeling to assess the within-individual associations and controlled for age and gender.
The results showed that shorter total sleep time in a single night predicted greater depressive symptoms the following day (P = .028). Additionally, sleep quality was found to have a negative association with next-day depression at the between-individual level (P = .003). Negative reactivity was observed to partially mediate the relationship between the quality of the participants’ sleep and depressive symptoms (P = .008), total sleep time and depression (P = .11), and sleep efficiency and depression (P = .002) at the between-individual level.1
The researchers said that in addition to finding an association between daily sleep time and depression, their findings suggested, “that one of the facets of emotion regulations, namely negative reactivity, plays a mediating role in the insomnia-depression relationship.” However, emotional reactivity and emotion regulation strategy use may not vary substantially across days.
Nocturnal Suicide and Possible Risk Factors
Suicide risk is greater at night after adjusting for population wakefulness, which researchers have hypothesized may be due to sleep- and circadian-dependent changes in neurophysiology to promote sleep. However, the characteristics of people who die by nocturnal suicide may differ from those who die by suicide during the day.
Researchers conducted an archival analysis of the National Violent Death Reporting System from 2003 to 2017 and identified 77,784 suicide deaths with the time of fatal injury. Cases that occurred between 5 a.m. and 10:59 p.m. were considered daytime suicides and cases that occurred between 11: p.m. to 4:59 a.m. were considered nocturnal suicides. All cases were categorized by age, sex, race, ethnicity, marital status, military service, education, history of suicidal thoughts, and prior diagnosis of anxiety, bipolar disorder, depression, post-traumatic stress disorder (PTSD), and schizophrenia. The presence of an opiate or cannabis and blood alcohol level (BAL) on autopsy were also considered.2
Every sociodemographic aspect included in the analysis was observed differently between nocturnal and daytime suicides. Nocturnal suicides were more common among those who were diagnosed with bipolar disorder or PTSD, had an elevated BAL, or had tested positive for cannabis.
Additionally, nocturnal suicide among people with a high BAL was more common in younger adults between the ages of 35 and 64 years. Notably, the risk of nocturnal suicide was 17% greater among those with a prior history of suicidal ideation and 13% lower among those diagnosed with depression.
“Further research is needed to target suicide prevention efforts at appropriately times for those with mood, substance, and alcohol use disorders,” the researchers wrote.
Reference
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
2 Commerce Drive
Cranbury, NJ 08512